Principal Financial Group Inc. purchased a new position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 89,447 shares of the company's stock, valued at approximately $808,000. Principal Financial Group Inc. owned about 0.32% of Delcath Systems as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of DCTH. Riverwater Partners LLC acquired a new position in shares of Delcath Systems during the 3rd quarter valued at about $161,000. Levin Capital Strategies L.P. increased its position in Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company's stock worth $262,000 after purchasing an additional 5,969 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Delcath Systems in the second quarter valued at approximately $370,000. Renaissance Technologies LLC purchased a new stake in Delcath Systems during the 2nd quarter worth $694,000. Finally, Marshall Wace LLP boosted its position in Delcath Systems by 7.0% in the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company's stock valued at $776,000 after buying an additional 6,066 shares during the last quarter. 61.12% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. Stephens reaffirmed a "buy" rating on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group restated a "buy" rating and set a $21.00 price objective on shares of Delcath Systems in a report on Friday, October 18th. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of Delcath Systems in a report on Monday, November 11th. Finally, StockNews.com upgraded Delcath Systems from a "sell" rating to a "hold" rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.50.
Get Our Latest Research Report on Delcath Systems
Delcath Systems Price Performance
NASDAQ:DCTH traded down $0.09 during midday trading on Friday, reaching $9.76. 640,170 shares of the company traded hands, compared to its average volume of 439,768. The firm has a market capitalization of $312.07 million, a price-to-earnings ratio of -7.23 and a beta of 0.75. The company has a fifty day moving average price of $9.68 and a 200 day moving average price of $8.66. Delcath Systems, Inc. has a twelve month low of $2.60 and a twelve month high of $12.88.
Delcath Systems Profile
(
Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Read More
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
